ANNOUNCEMENT OF ANNUAL RESULTS FOR 2024
Notable Progress in R&D and Commercialization Gross Profit Surging 68% FINANCIAL HIGHLIGHTS • Revenue was approximately RMB1,933.0 million, representing a year-on-year increase of 25.5%. • Gross profit was approximately RMB1,273.7 million, representing a year-on-year increase of 67.8%. • Research and Development Expenses was approximately RMB1,206.1 million, representing...
Innovent Announces 2024 Annual Results and Business Updates
First-ever positive profit, entering a new era of growth and global innovation SAN FRANSISCO and SUZHOU, China, March 26, 2025 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announces its 2024 annual results, including major business...
NEURIM PHARMACEUTICALS RECEIVES EUROPEAN MARKETING AUTHORIZATION FOR PEDIATRIC PROLONGED-RELEASE MELATONIN (SLENYTO®) FOR THE TREATMENT OF INSOMNIA IN CHILDREN WITH ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
TEL AVIV, Israel, March 26, 2025 /PRNewswire/ -- Neurim Pharmaceuticals ("Neurim") announces that the European Commission has approved the extension of the indication to include the treatment of insomnia in children with attention deficit hyperactivity disorder (ADHD). The European Commission decision followed the recommendation of the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency...
Antengene to Present Results From Four Cutting Edge Preclinical Studies at AACR 2025 with Focuses Including AnTenGagerTM TCEs and Synthetic Lethality
SHANGHAI and HONG KONG, March 26, 2025 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for hematologic malignancies and solid tumors, today announced that it will release results from four preclinical studies in poster presentations at...
Fangzhou Inc. Partners with Tencent Health and Tencent Cloud to Accelerate Development of AI-Enabled Healthcare Services
SHANGHAI, March 26, 2025 /PRNewswire/ -- Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a leader in Internet healthcare solutions, announced a strategic collaboration with Tencent Health and Tencent Cloud to accelerate AI-driven healthcare solutions by integrating the DeepSeek open-source AI Model on its platform. Following on the Company's local deployment of...
GenScript Biotech Earns EcoVadis Bronze Medal for the Second Consecutive Year, Ranking Above 83% of Companies
PISCATAWAY, N.J., March 26, 2025 /PRNewswire/ -- GenScript Biotech Corporation (GenScript), a global leader in life sciences research, manufacturing technologies and production services, has been awarded the EcoVadis Bronze Medal for the second year in a row, recognizing its strong sustainability performance. This achievement reflects GenScript's continued progress in environmental stewardship, labor and human rights, ethics, and sustainable procurement,...
NUS researchers develop microneedle technology to accelerate diabetic wound healing
'Sponge-like' microneedle patches deliver bioactive ingredients and reduce inflammation in slow- and non-healing wounds SINGAPORE, March 26, 2025 /PRNewswire/ -- Diabetic wounds often lead to severe complications that can result in amputations. These chronic and non-healing wounds are marked by persistent inflammation, affecting more than six per cent of the global population. In Singapore, there are about four lower...
Gene Solutions Leads the Way in Cancer Early Detection with Asia’s First Clinical Validated Multi-Cancer Blood Test
SINGAPORE, March 26, 2025 /PRNewswire/ -- Gene Solutions, a leading biotech company in Asia, proudly announces a groundbreaking achievement in cancer early detection. The company's innovative SPOT-MAS test has become the first multi-cancer screening blood test in Asia to complete large prospective cohort validation, as published in BMC Medicine. This milestone marks a major advancement, enabling large-scale, non-invasive early...
Singapore’s Best Workplaces in Healthcare & Biopharma™ 2025 Announced, Showcasing Insights from Nearly 10,000 Employees
SINGAPORE, March 26, 2025 /PRNewswire/ -- Great Place To Work®, the global authority on workplace culture, has officially announced Singapore's Best Workplaces in Healthcare & Biopharma™ 2025 list, celebrating 10 pioneering healthcare and biopharma companies that have created exceptional workplace cultures. Now in its third year since the list's inaugural launch, this recognition...
Alphamab Oncology Reports Full Year 2024 Financial Results and Business Highlights
SUZHOU, China, March 26, 2025 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) reported financial results for the full year ended December 31, 2024 and highlighted recent business progress. Financial Summary For the year ended December 31, 2024, we recorded total revenue of RMB 640.08 million, a 192.58% year-on-year increase. Meanwhile, product revenue (attributed to the Company) amounted to...
